Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND-1: ANV600 +/- Pembrolizumab in Advanced Solid Tumors
NCT06470763Phase 2Completed
- Sponsor
- Anaveon
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Fc-Fusion Proteins
- Countries
- 7
01
Overview
Phase 2, open-label trial of ANV600 in solid tumor, melanoma, non-small cell lung cancer (NSCLC) and 1 more (2 arms), sponsored by Anaveon. Primary endpoints: Dose Limiting Toxicities at 24 months, Treatment-Emergent Adverse Events at 24 months and 2 more. Started Jul 2024; status: completed.
02
Drugs
ANV600
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06470763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470763.